SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending due to recent service outages affecting its 365 suite and ongoing debate surrounding its AI strategy and investment in OpenAI, amplified by Elon Musk's lawsuit. While some investors see current price levels as an opportune moment to buy a fundamentally strong company, others point to broader mega-cap tech weakness and competitive pressures as key drivers of the decline ahead of its earnings report.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed (PAVM) is trending due to news that its subsidiary, Lucid Diagnostics, secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access across the VA healthcare system. This has ignited intense market activity and debate, with some investors anticipating significant further upside given the contract's potential and the company's low share float, while others express caution regarding extreme price volatility and the potential for future share offerings.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is experiencing significant volatility amid intense community debate, driven by reports of potential lawsuits from bondholders concerning the financing of its large-scale AI infrastructure projects and substantial debt. While some investors view the recent price action as a major buying opportunity given Oracle's strategic position in cloud and AI, others are wary of the financial liabilities and the long-term impact on the company. The ongoing speculation regarding a significant TikTok deal is also a key point of discussion, contributing to divergent market sentiment.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is experiencing a notable sell-off, generating intense community discussion over its future. While many express strong bearish sentiment citing competition in the GLP-1 market and perceived threats from Amazon, others view the downturn as an oversold buying opportunity, emphasizing the company's expanding personalized healthcare platform and vertical integration.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is a focal point for intense market volatility, driven by shifting geopolitical narratives concerning presidential statements on Greenland and evolving US-EU trade relations. Community sentiment is sharply divided, with some anticipating continuous "V-shape" rallies and "buy the dip" opportunities fueled by perceived pro-market stances, while others remain highly skeptical, warning of orchestrated pump-and-dump scenarios and a looming market decline. This tug-of-war reflects deep uncertainty within the tech-heavy Nasdaq, where bullish convictions clash with cautious perspectives on broader economic stability.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai (BBAI) is trending due to an upcoming pivotal shareholder vote on increasing authorized shares, which has polarized the community. While some investors fear potential dilution, many anticipate the approval will unlock significant growth, enabling future contracts and strategic moves in the government AI and defense sectors that could drive a substantial re-rating.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following news of a significant French government-backed deal to establish a rare earth metals and alloys production facility in Europe, aiming to bolster the integrated supply chain for the U.S. and its allies. This development, alongside broader sector momentum driven by geopolitical dynamics and the launch of new leveraged ETFs, is fueling community discussions about the company's long-term potential and notable price volatility. Traders are actively discussing the broader implications of securing critical minerals supply chains and the company's "mine-to-magnet" strategy amidst ongoing market swings.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is trending following its selection for the U.S. Missile Defense Agency's SHIELD contract, a significant validation of its capabilities in defense AI that positions it for substantial 'Golden Dome' task orders. The community is actively discussing the company's expanding footprint into sovereign AI initiatives, particularly in the Middle East, with many viewing recent price dips as strategic buying opportunities. This perceived shift toward high-value government and international AI contracts is fueling anticipation for a significant re-rating of INOD's valuation.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending after reporting strong Q4 results driven by subscriber and ad revenue growth, though its stock faces downward pressure from softer Q1 guidance and ongoing speculation around a potential Warner Bros. Discovery acquisition. The community is sharply divided, with many viewing the dip as a prime buying opportunity for a market leader, while others anticipate further declines given the acquisition's perceived risks and potential for market manipulation.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is trending following its recent acquisition of a critical minerals flotation facility, strengthening its integrated processing capabilities amidst a heightened national security focus. The community is actively discussing the company's unique position as a domestic antimony producer, anticipating significant government investment in critical mineral supply chains and potential for substantial upside. Many are closely watching for further strategic announcements as geopolitical tensions underscore the importance of securing domestic resource supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) has received an average rating of "Moderate Buy" from the five ratings firms that are covering the stock, MarketBeat.com reports. One...

Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% - What's Next?

Rani Therapeutics (NASDAQ:RANI) Trading Down 2.2% - Time to Sell...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five ratings firms that are covering the stock...

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why

Rani Therapeutics (NASDAQ:RANI) Stock Price Up 1.3% - Here's Why...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock...

Investors Purchase High Volume of Put Options on Rani Therapeutics (NASDAQ:RANI)

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) was the recipient of some unusual options trading activity on Thursday. Stock investors acquired 12,455 put options on the stock. This...

Rani Therapeutics (NASDAQ:RANI) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Rani Therapeutics (NASDAQ:RANI - Get Free Report) released its earnings results on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus...

Rani Therapeutics Holdings Inc. (RANI) on Friday announced that it has entered into a strategic collaboration with Chugai Pharmaceutical Co., aiming to advance the development of an oral therapeutic using its proprietary RaniPill technology.&nbsp;Chugai will work with Rani to create and commercialize a new oral product based on an experimental antibody for rare diseases. Under the deal, Rani will receive $10 million upfront.Beyond the upfront payment, Rani may earn up to $75 million in development-related milestones, another $100 million based on commercial achievements, and single-digit royalties on sales once the product reaches the market. The agreement grants Chugai an initial license for one drug target, with the possibility of expanding to five more. The total potential payments could reach $1.085 billion if all options are exercised.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/RANI">Rani Therapeutics' stock</a> traded over 165% higher in Friday’s premarket. On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;By partnering with Chugai, the company gains access to a promising rare disease pipeline while reinforcing its financial position.&nbsp;&nbsp;“There are many cases where oral therapies for the treatment of multiple disease areas with high unmet medical needs, including rare and immunologic diseases, are limited and as a result, patients rely primarily on injections that can be burdensome and impact adherence,” said Rani CEO, Talat Imran.&nbsp;&nbsp;In a parallel move, Rani announced a private placement financing expected to generate about $60.3 million in gross proceeds.Rani Therapeutics’ stock has lost over 65% in 2025 and over 82% in the past 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stellantis-joins-hands-with-pony-ai-to-power-self-driving-vans-in-europe/ch6sdh6R3FD">Stellantis Stock Edges Up Premarket: Legacy Auto Giant Joins Hands With China's Pony AI To Power Self-Driving Vans In Europe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is Rani Therapeutics’ Stock Skyrocketing Pre-Market Today?

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.

Equity

The total potential payments from the collaboration could reach $1.085 billion if all options are exercised.


These five health care stocks, all belonging to small- or micro-cap categories, notched the highest jump in Stocktwits followers in the week ended Feb. 7, 2025:GH Research PLC (+103% jump in followers)&nbsp;GH Research PLC focuses on developing mebufotenin-based therapies for treatment-resistant depression. The company’s inhalable candidate, GH001, met its primary endpoint in a Phase 2b trial, showing a significant reduction in depression scores compared to placebo. Secondary endpoints also showed improvements, with no serious adverse events reported.&nbsp;Despite the promising data, GHRS stock fell more than 28% over the past week.Lipella Pharmaceuticals Inc. (+40% jump in followers)Lipella Pharmaceuticals received FDA approval for an Expanded Access Program for LP-310, an oral rinse for treating oral lichen planus. The condition affects around 6 million Americans and currently has no FDA-approved therapies. The program allows patients with serious unmet medical needs to access the treatment outside of clinical trials.&nbsp;Following the announcement, LIPO stock climbed nearly 14% last week.MBX Biosciences Inc. (+39% jump in followers)MBX Biosciences, focused on peptide therapies for endocrine and metabolic disorders, had no major catalyst last week. However, in January, the company reported positive results from a Phase 1 trial of its long-acting GLP-1 receptor antagonist, MBX 1416, which showed a favorable safety profile.&nbsp;MBX shares surged more than 25% over the past week.Rani Therapeutics Holdings Inc. (+29% jump in followers)Rani Therapeutics, which is developing oral alternatives to injectable biologics, shared new preclinical data on its RaniPill capsule for delivering semaglutide. The study showed successful drug delivery with bioavailability and weight-loss effects comparable to subcutaneous administration. The company plans to start Phase 1 trials of a GLP-1/GLP-2 dual agonist in 2025.&nbsp;RANI stock rose over 12% last week.Invivyd Inc. (+21% jump in followers)Invivyd, which focuses on monoclonal antibodies for viral diseases, reported positive data from its ongoing Phase 1/2 trial of VYD2311, a potential alternative to COVID-19 vaccines. The candidate showed strong antiviral activity and a promising safety profile. The data, combined with results from its Phase 3 CANOPY trial, support its potential as a long-acting COVID-19 treatment.&nbsp;Invivyd shares soared over 355% last week.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

These 5 Health Care Stocks Saw The Sharpest Retail Interest Jump Last Week

These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

RANI
Rani Therapeutics Holdings Inc - Ordinary Shares Class A

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest RANI News

RANIRani Therapeutics Holdings Inc - Ordinary Shares Class A